Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-12 10:44:42 ET
Organon & Co. (OGN) Q4 2025 Earnings Call February 12, 2026 8:30 AM EST
Company Participants
Jennifer Halchak - Head of Investor Relations
Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply
Matthew Walsh - Executive VP & CFO
Carrie Cox - Executive Chairman of the Board
Juan Camilo Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer
...
Read the full article on Seeking Alpha
For further details see:
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Organon & Co.
NASDAQ: OGN
OGN Trading
-1.9% G/L:
$6.46 Last:
859,864 Volume:
$6.50 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
